Immunization with synthetic SARS-CoV-2 S glycoprotein virus-like particles protects macaques from infection.
Cell Rep Med
; 3(2): 100528, 2022 02 15.
Article
em En
| MEDLINE
| ID: mdl-35233549
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has caused an ongoing global health crisis. Here, we present as a vaccine candidate synthetic SARS-CoV-2 spike (S) glycoprotein-coated lipid vesicles that resemble virus-like particles. Soluble S glycoprotein trimer stabilization by formaldehyde cross-linking introduces two major inter-protomer cross-links that keep all receptor-binding domains in the "down" conformation. Immunization of cynomolgus macaques with S coated onto lipid vesicles (S-LVs) induces high antibody titers with potent neutralizing activity against the vaccine strain, Alpha, Beta, and Gamma variants as well as T helper (Th)1 CD4+-biased T cell responses. Although anti-receptor-binding domain (RBD)-specific antibody responses are initially predominant, the third immunization boosts significant non-RBD antibody titers. Challenging vaccinated animals with SARS-CoV-2 shows a complete protection through sterilizing immunity, which correlates with the presence of nasopharyngeal anti-S immunoglobulin G (IgG) and IgA titers. Thus, the S-LV approach is an efficient and safe vaccine candidate based on a proven classical approach for further development and clinical testing.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Vacinação
/
Vacinas de Partículas Semelhantes a Vírus
/
Glicoproteína da Espícula de Coronavírus
/
Vacinas contra COVID-19
/
SARS-CoV-2
/
COVID-19
Limite:
Animals
/
Humans
/
Male
Idioma:
En
Ano de publicação:
2022
Tipo de documento:
Article